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Abstract
Background: Maturity onset diabetes of the young type 2 (or GCK MODY) is a genetic form of diabetes mellitus provoked by
mutations in the glucokinase gene (GCK).
Methodology/Principal Findings: We screened the GCK gene by direct sequencing in 30 patients from South Italy with
suspected MODY. The mutation-induced structural alterations in the protein were analyzed by molecular modeling. The
patients’ biochemical, clinical and anamnestic data were obtained. Mutations were detected in 16/30 patients (53%); 9 of
the 12 mutations identified were novel (p.Glu70Asp, p.Phe123Leu, p.Asp132Asn, p.His137Asp, p.Gly162Asp, p.Thr168Ala,
p.Arg392Ser, p.Glu290X, p.Gln106_Met107delinsLeu) and are in regions involved in structural rearrangements required for
catalysis. The prevalence of mutation sites was higher in the small domain (7/12: ,59%) than in the large (4/12: 33%)
domain or in the connection (1/12: 8%) region of the protein. Mild diabetic phenotypes were detected in almost all patients
[mean (SD) OGTT=7.8 mMol/L (1.8)] and mean triglyceride levels were lower in mutated than in unmutated GCK patients
(p=0.04).
Conclusions: The prevalence of GCK MODY is high in southern Italy, and the GCK small domain is a hot spot for MODY
mutations. Both the severity of the GCK mutation and the genetic background seem to play a relevant role in the GCK
MODY phenotype. Indeed, a partial genotype-phenotype correlation was identified in related patients (3 pairs of siblings)
but not in two unrelated children bearing the same mutation. Thus, the molecular approach allows the physician to confirm
the diagnosis and to predict severity of the mutation.
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Introduction
Maturity onset diabetes of the young (MODY; MIM #606391)
is a genetically and clinically heterogeneous form of diabetes
mellitus, characterized by an early age at onset, a primary defect in
beta-cell function and an autosomal dominant inheritance [1].
Among the different types of MODY diabetes described thus far,
each of which is due to a different gene mutation (HNF4A, GCK,
HNF1A, IPF1, HNF1B, NEUROD1, CEL) [2,3] the GCK
MODY form is provoked by mutations in the glucokinase gene
(GCK; MIM#138079).
The glucokinase gene on chromosome 7p15.3-p15.1 consists of
12 exons that span ,45.169 bp and encode a 465-amino-acid
protein [4], and three tissue-specific isoforms are known [5]. Thus
far, about 200 GCK mutations have been reported and its
frequency is higher in European Caucasians, particularly in those
from France and Italy [6]. The identification of a GCK mutation
in subjects whose clinical phenotype is suggestive of MODY
usually distinguishes patients with a benign prognosis (GCK
MODY) from those with a severe hyperglycemia (HNF1A MODY
and other MODY forms) because the diagnosis cannot be always
made on clinical grounds alone.
Glucokinase (also called hexokinase IV) catalyzes the ATP-
dependent phosphorylation of glucose to glucose-6-phosphate. It is
homologous to hexokinases I, II and III, but its lower affinity for
glucose, restricted localization to a few cell types and peculiar
kinetic properties, compared to those of the other hexokinases,
confer it distinctive properties. Indeed, GCK acts as a glucose
sensor in the pancreas and liver, and presents a peculiar sigmoidal
glucose saturation curve, which indicates cooperative behaviour.
Elucidation of crystal structure of GCK yielded data that could
help to establish structure-function correlations [7]. Indeed, the
protein folds into two domains known as the small and the large
domain with the glucose binding site in between. An unexpected
‘‘super-open’’ form and a ‘‘closed’’ form of the enzyme were
identified [7]; the latter is similar to the form found in the
hexokinase I structure [8]. The two forms differ in the relative
spatial orientation of the two domains. The catalytic mechanism
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1870requires dramatic GCK conformational changes. In fact, when
bound to glucose, the enzyme goes from the super-open inactive
form to the closed form. Therefore, the inter-domain motions are
crucial for the enzyme activity.
In this study, we report the identification of 9 novel and 3
known mutations of the GCK gene in children from south Italy. All
mutations co-segregated with the diabetic phenotype in the
respective families and resulted in perturbation of the 3D structure
of the protein. Our data show that molecular screening is useful in
the diagnosis of MODY because it allows to confirm the diagnosis
and to predict severity of the mutation.
Methods
Subjects
Thirty patients aged 1–14 years, 9 boys and 21 girls whose
clinical presentation was suggestive of MODY were selected for
GCK gene screening from among 240 diabetic children seen in the
Paediatric Clinic of our Medical School between 2001 and 2006.
Other MODY genes were not investigated. Most patients were
unrelated; 6 were except (3 pairs of siblings, 1: M022–M023, 2:
M024–M025, 3: M028–M029). Inclusion criteria were: early onset
(,25 years) of diabetes, mild hyperglycemia, no autoimmune
markers of type I diabetes, without obesity [c.o. body mass index
(BMI) z score .2] and family history of diabetes for at least two
consecutive generations [1,9]. No treatment was administered to
the patients and no diabetes complications were evident up to
diagnosis. A fasting blood sample was drawn from both parents of
mutated patients and from 100 unrelated controls, who came from
the same geographical area, and used for the GCK molecular
characterization. The parents of all subjects gave their written
informed consent to the study. The research was conducted
according to Helsinki II declaration and approved by the ethics
committee of our Faculty.
Clinical and anamnestic examination
We collected the following data for each patient upon
diagnosis: age, birth weight, family history of diabetes and/or
other diseases and BMI. The BMI was transformed into BMI-z-
score (z-BMI) based on the Centre for Disease Control normative
curves [10,11].
Biochemical analyses
The following biochemical parameters were measured on
fasting blood samples: plasma glucose (FPG) by the enzymatic
hexokinase method and triglycerides by the standard enzymatic
method (Hitachi Modular, Tokyo, Japan); glycosylated haemo-
globin (HbA1c) by HPLC (HLC-723 G7 TOSOH Bioscience
Tokyo, Japan); serum insulin by the chemiluminescence method
(Immulight 2000; Medical System Genoa, Italy). After an oral
glucose dose of 0.75g/kg body weight (maximum 75 g), oral
glucose tolerance test (OGTT) was evaluated on blood samples
collected every 30 min up to 2 h. The first-phase insulin response
(FPIR) was calculated as the sum of T+1 and +3 min serum insulin
concentrations, evaluated after an i.v. glucose dose of 0.5 g/kg
body weight in 3 min [12].
DNA extraction
Genomic DNA from patients, parents and controls was
extracted from a blood sample plus EDTA using Nucleon BACC
2 kit (Amersham Biosciences Europe, Milan, Italy).
Sequence analysis
Exons and flanking intron regions of GCK, including tissue
specific variants of exon 1, were amplified by PCR using
previously reported primers (exons 1a, 2, 3, 4) [13] or chosen by
the Primer 3 program (exons 1b, 1c, 5, 6, 7, 8, 9 and 10) [14]. The
PCR mixture contained in a final volume of 50 ml: 20 mM each
primer, 1x PCR buffer (Applied Biosystems, Foster City, CA,
USA), 10 mM each deoxynucleotide triphosphate, 2.5 U of Taq
DNA polymerase (Applied Biosystems) and 200 ng of genomic
DNA. Each PCR was performed on Gene-Amp PCR system 9700
thermocycler (Applied Biosystems) and consisted of a initial
denaturation step at 95uC for 5 min and a final extension at
72uC for 7min.
The primers and PCR conditions are detailed in table 1.
Product sizes were evaluated by agarose gel electrophoresis and
amplicons were sequenced in both directions using the Big Dye
terminator sequencing kit (Applied Biosystems) on ABI PRISM
sequencing apparatus 3730 (Applied Biosystems). We preliminarily
analyzed the GCK coding sequence of a healthy subject by
sequence analysis and verified that it overlapped the wild-type
reference sequence (GenBank NM_000162). All sequences of the
Table 1. Primers used for PCR amplification of GCK exons and PCR conditions.
Exons
1 Forward primer Reverse primer
PCR annealing
temperatures
PCR annealing
times
PCR extension
times (72uC)
Number of
cycles
1a
(2) 59-TCCACTTCAGAAGCCTACTG 59-TCAGATTCTGAGGCTCAAAC 60uC 30’’ 60’’ 35
1b 59-AGCAGGCAGGAGCATCTCTG 59-GCTGCTCTCCCAGTGCAAAG 62uC 20’’ 60’’ 30
1c 59-GGCCAACTGCTACTTGGAAC 59-AGGAGGTGAGAAGCCTGGAG 54uC 20’’ 30’’ 35
2
(2) 59-TGCAGATGCCTGGTGACAGC 59-CACAGCTGCTTCTGGATGAG 60uC 15’’ 30’’ 30
3
(2) 59-TAATATCCGGCTCAGTCACC 59-CTGAGATCCTGCATGCCTTG 57uC 15’’ 30’’ 30
4
(2) 59-TAGCTTGGCTTGAGGCCGTG 59-TGAAGGCAGAGTTCCTCTGG 62uC 20’’ 60’’ 30
5/6 59-TCTGAGCCTGTTTCCTCAGC 59-GGCCCTTGAAGCCTGTTGTA 57uC 20’’ 45’’ 35
75 9-CCAGACAAAGCAGAGACAGG 59-TGCTTTTCCCCAGAGTTGTT 54uC 20’’ 45’’ 35
85 9-TGGCTCATTAACGAGGGAAA 59-CTGAGACCAAGTCTGCAGTG 51uC 15’’ 45’’ 35
95 9-CCCTCCCTGGAGAACGAGAG 59-AATCTTGGAGCTTGGGAACC 60uC 20’’ 45’’ 35
10 59-GAGTCTTCTCGACCCCCTTG 59-CACCGAAAAACTGAGGGAAG 55uC 20’’ 45’’ 35
1GenBank: accession nu (AH005826)
2Taken from Stoffel M. et al. 1992 Proc Natl Acad Sci USA 89:7698–7702.
doi:10.1371/journal.pone.0001870.t001
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reference sequence with the ABI Seqscape software v2.5 (Applied
Biosystems).
All mutations were also validated on a second PCR product.
Finally, the children’s parents and 100 unrelated healthy
individuals were screened for these mutations.
Conservation of residues was evaluated from a multiple
sequence alignment of 15 sequences in the PFAM349 and
PFAM3724 protein families [15]. The result was validated by a
multiple sequence alignment of 341 protein sequences homolog to
GCK and extracted from the non redundant sequence database
RefSeq, available online [16]. Furthermore, for the 1v4s structure,
a multiple sequence alignment of 143 sequences in the
ConSurf_HSSP database [17] was carried out. The outcomes
from the three approaches were in accordance.
Statistical analysis
Continuous variables are reported as mean (SD) and compar-
isons among variables were made with the t- test. Inter-group
differences were considered statistically significant at p,0.05.
We calculated the distribution in the large domain, in the small
domain and in the connection region of the protein of our GCK
mutations and of those described in literature.
Mutations nomenclature
All mutations are described according to the recommended
nomenclature available online [18–20]. Nucleotide numbers are
derived from cDNA GCK sequence (GenBank NM_000162)
considering nucleotide +1 the A of the first ATG translation
initiation codon in the reference sequence.
Molecular modelling
We used molecular modelling to investigate alterations of the
GCK 3D structure and dynamics associated to the various
mutations. The active form of GCK served as template because it
has the highest resolution structure (2.3 A ˚, PDB code: 1v4s) [7].
Under the assumption that point mutations are likely to preserve
the overall fold of the proteins, it follows the procedure for
generating models. The first step of this procedure is the prompt
substitution of the residues, which we did with the program
MODELLER [21]. The program replaces the side chains by
selecting the most abundant conformers and performs a simulated
annealing procedure to optimize side chain conformations. This
was followed by energy minimization in explicit solvent with the
GROMACS program [22] using the GROMOS96 force field
[23]. Finally, the system was optimized by means of a short
molecular dynamics calculation of 1ns. The calculation was made
by restraining the main chain conformations and allowing the side
chain dynamics. The notation used for secondary structure was
taken from Kamata et al. [7]. Accordingly, sequences 1–64 and
206–439 belong to the large domain, sequences 72–201 and 445–
465 belong to the small domain, and sequences 65–71, 202–205
and 440–444 belong to the three loops connecting the domains.
Results
Table 2 shows the molecular characterization of the 16/30 our
diabetic children who had mutations in the GCK gene. Ten
patients were unrelated (two of these had the same mutation) and 6
were siblings from 3 families. Therefore, GCK MODY diagnosis
was confirmed in these 16 patients. All mutations were detected at
the heterozygous state, 9 mutations were novel; 8 of them caused
variations in amino acid residues well conserved among species,
and one produced a truncated protein of 289 amino acids
(p.Glu70Asp, p.Phe123Leu, p.Asp132Asn, p.His137Asp,
p.Gly162Asp, p.Thr168Ala, p.Arg392Ser, p.Glu290X,
p.Gln106_Met107delinsLeu). Three other GCK mutations were
already known; 2 of them caused truncated proteins (p.Lys39fsX6
and p.Ser453X) [24,25] and 1 was a missense mutation
(p.Glu265Lys) (Bellane ´-Chantelot C et al. Abstract, Diabetologia
1998; 41:A109, 423). The structural analysis of mutation sites
indicated 3D clustering. In fact, among the GCK variants in our
population, 7/12 (,59%), 4/12 (33%) and 1/12 (8%) were
localized in the small domain, in the large domain and in the
connecting loops, respectively (Fig. 1). The effects of GCK
mutations on the enzyme’s 3D structure are reported in Table 2.
Figures 2 and 3 show the structural features of some of the new
mutations detected in our GCK MODY patients.
Table 3 shows the phenotypic characteristics of our mutated
children at diagnosis. All mutations were also present in either the
mother or the father of the GCK MODY patients in association
with diabetes and mean birth weight did not differ between
children who inherited GCK mutations from their father or
mother (2.84 kg vs 2.98 kg). Almost but one patient had mild
hyperglycemia [mean (range) FPG=6.60 (5.7–7.9) mmol/L,
M013=10.0 mmol /L], mildly altered OGTT [mean (SD) 2 h
OGTT=7.8 (1.8) mmol/L] and 2h increment always ,2.8 except
in two patients: M024=3.3 and M005=4.9; FPIR values between
24.6 and 156.0 mU/mL and slightly elevated levels of HbA1c
[mean (SD) HbA1c=6.1 (0.4) %]. The mean triglyceride
concentration (0.58 mmol/L) was lower in our mutated patients
(p=0.04) than in unmutated GCK MODY patients (0.80 mmol/
L) and below 50
th percentile of our laboratory age-related
reference range (0.36–1.10 mmol/L).
Discussion
In our Italian population, GCK gene mutations account for 6%
(16/240) diabetic children and for 53% (16/30) with suspected
MODY. This GCK MODY prevalence is in line with those
detected in southern European countries, particularly in France
and in Italy, namely between 8% and 56% [25–27]. An analysis of
the 3D structure of the protein mutants yielded evidence of
structural perturbations, which supports the GCK MODY-
causing nature of these mutations. In particular, the p.Glu70Asp
mutation (detected in 1 patient) substitutes the highly conserved
glutamate with aspartate. These amino acids are polar acidic
residues but the binding to lysine 458, in the a13 helix, appears to
be weakened compared with the wild-type enzyme. This
substitution could slightly modify enzymatic activity and/or
stability. Substitution of glutamate by lysine is reported, in
association with diabetes, to reduce the enzyme’s glucose affinity
but protein stability is preserved [28].
The p.Gln106_Met107delinsLeu mutation (detected in 1
patient) altered respectively, a poorly and moderately conserved
amino acid. It produces a protein in which residues Gln106 and
Met107 are substituted by a leucine. This mutation occurs on an
edge strand of the b-sheet of the small domain. The b-sheet
encompasses the a13 helix in the closed form. Because the
conformational features of this region are essential for super-open/
closed conversion, the deletion could influence GCK function. A
gene deletion encompassing GCK exon 2 (p.Val16_Glu70del) has
recently been described in a UK diabetic patient by multiplex
ligation-dependent probe amplification assay and it co-segregated
with early onset diabetes within the pedigree [29]. The
p.Phe123Leu mutation (detected in 1 patient) altered a highly
conserved amino acid. Phe 123 is located on the a3 helix within
the small domain. Phe 123 is projected into the hydrophobic core
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PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1870of the domain thereby contributing to its stability. The substitution
of a phenylalanine with a leucine is not dramatic in terms of
hydrophobicity, however, it introduces a cavity in the hydrophobic
core. This may affect inner surface complementarity thereby
influencing the structural stability and the dynamical behaviour of
the domain with consequences at a functional level.
In mutant p.Asp132Asn (detected in 2 related patients), the
acidic negatively charged aspartate, located in the a3 helix that
belongs to the small domain, is changed into the uncharged
asparagine. Aspartate 132 is a poorly conserved amino acid and
this variant probably provokes only mild structural alterations. In
fact, the 2 siblings bearing this mutation had normal glucose
tolerance. The p.His137Asp mutation (detected in 1 patient)
altered a moderately conserved amino acid. The activity of hepatic
GCK is regulated by the glucokinase regulatory protein (GKRP).
This would act as an allosteric inhibitor of GCK that specifically
binds to the super-open form. Indeed, mutational analyses [30]
have shown that two GCK fragments, 51–52 and 141–144, are
involved in such interactions. Sequence 141–144 follows the a3
helix that is terminated by His 137. Histidine, by interacting with
the carbonyl of Phe133, is involved in helix capping. Mutation
p.His137Asp introduces a negative charge in the region and, in
Figure 1.Distribution ofthe GCKmutations.The structure ofGCK in
the closed form (PDB code: 1v4s) is shown as cyan and red ribbons that
represent the small and large domain, respectively. Orange ribbons show
the a13 helix. Yellow spheres are the mutation sites. Red and blue circles
indicate clusters of mutations in the large and small domain, respectively.
doi:10.1371/journal.pone.0001870.g001
Figure 2. Structural features of mutations p.Phe123Leu and p.Asp168Ala GCK. The structure of GCK in the closed form (PDB code: 1v4s) is
represented by cyan ribbons. A) Mutation p.Phe123Leu. Phe123 is structured inside the hydrophobic core of the small domain. Yellow sticks
represent hydrophobic residues that constitute the core. Phe123 and Leu123 are represented by red sticks (left and right panel, respectively). B) The
sticks represent residue Thr168 and glucose. The right panels show a close-up view of the glucose-binding cleft for the wild-type (top) and for the
Ala168 mutant (bottom).
doi:10.1371/journal.pone.0001870.g002
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PLoS ONE | www.plosone.org 5 April 2008 | Volume 3 | Issue 4 | e1870our simulations, Asp137 does not exert a capping function, but
strongly interacts with Lys104 by making a salt bridge.
Accordingly, p.His137Asp may affect the conformational proper-
ties of fragment 141–144 thereby indirectly influencing the
binding with GKRP. The p.His137Arg mutation has been
described in association with diabetes [31].
The p.Gly162Asp mutation (detected in 1 patient) altered a
highly conserved amino acid. Gly162 is located on the b-sheet that
encloses the small domain hydrophobic core. p.Gly162Asp is one
of the most dramatic mutations we identified because it introduces
a negative residue inside the hydrophobic core. p.Gly162Asp very
probably influences the stability of the core thereby altering the
structure and dynamics of the domain. This scenario is indicative
of functional impairment of the enzyme.
The p.Thr168Ala mutation (detected in 2 related patients)
affected a conserved amino acid. The glucose-binding cleft is
located at the interface between small and large domains. It is
constituted by residues Glu256 and Glu290 from the large
domain, Thr168 and Lys169 from the small domain, and
Asn204 and Asp205 from the interconnecting region. Binding a
glucose molecule requires a precise pattern of H-bonds between
the substrate and GCK. Thr168 binds glucose, therefore the
p.Thr168Ala substitution prevents the formation of the H-bond
and probably perturbs the enzyme’s binding affinity and efficiency.
Mutation p.Thr168Ala has been described in patients affected by
diabetes [32]; it greatly increased Vmax and resulted in a complete
loss of cooperative behaviour associated with glucose binding, the
2 siblings bearing this mutation had normal glucose tolerance and
impaired glycosylated hemoglobin. Glutamate 290 is a highly
conserved residue involved in glucose binding. The p.Glu290X
mutation (detected in 2 unrelated patients) introduces a stop codon
and generates a truncated protein of only 289 amino acids, which
is thus unable to function.
The p.Arg392Ser mutation (detected in 1 patient) alters a
conserved amino acid. Arg392, is located on the a11 helix in the
large domain and is involved in a local H-bond/salt bridge
network. Arg392 is positively charged and makes a salt bridge with
the negative residues Asp42 (a2) and Glu236. The H-bond
network extends to two water molecules and residue Asn240.
These residues, which are far in sequence, are relevant for the
tertiary structure of the domain, in fact serine is unable to replace
the wild-type Arg392 interactions. The p.Arg392Cys mutation was
reported in co-segregation with hyperglycemia in pregnancy [33].
Three patients carried already known GCK mutations:
p.Lys39fsX6, p.Ser453X and p.Glu265Lys. All these mutations
were described in association with hyperglycemia. In particular,
the Ser R Leu mutation at residue 453 was recently found to
reduce GCK activity in a GCK MODY patient [34]. In our GCK
MODY patients, the distribution of mutation sites in the GCK
protein (59%, 33% and 8% in the small domain, large domain and
in the connection region, respectively) differed from the distribu-
tion observed in European Caucasians and in other ethnic groups
(41%, 58% and 1% in the small domain, large domain and in the
connection region, respectively) [5,35]. Consequently, the GCK
small domain may be a hot spot for MODY mutations typical of
Southern Italy. Interestingly, almost all the mutation sites we
describe are in regions involved in structural rearrangements
required for catalysis. This finding supports the notion that
mutations may affect GCK function, which is intimately related to
intermotion domain [7]. Our data confirm the association
between low triglyceride values and GCK mutations and support
a low rate of cardiovascular complications in GCK MODY
diabetes [36]. Interestingly, the two patients (M001 and M013)
with the lowest BMI z scores also had the lowest FPIR values,
which is in line with the finding that, at low levels, insulin does not
exert an anabolic effect [37].
Massa et al. [25] did not find an association between phenotype
and genotype in GCK MODY patients. Two of our unrelated
patients, M001 and M006, who both carried the p.Glu290X
mutation, had a low birth weight but a different diabetic
phenotype as evaluated by OGTT, FPIR tests and triglyceride
level. In contrast, among the three pairs of siblings, each with the
same mutation, two pairs (M022-M023, M028-M029) had almost
identical metabolic phenotypes. In the third pair of siblings (M024-
M025, aged 12 and 5 years respectively), the elder child was
diabetic and the younger had impaired glucose tolerance. In these
two patients, the p.Glu265Lys mutation provoked a dramatic
rearrangement of GCK, which indicates a more severe prognosis.
Thus, both the severity of the GCK mutation and the genetic
background seem to play a relevant role in the GCK MODY
phenotype.
In conclusion, all mutations detected in our diabetic children
from south Italy co-segregated with the diabetic status in one or
two family members of each patient and were not detected during
the screening of 200 normal chromosomes. The new deletion and
missense mutations produced an amino acid substitution at
positions that are well conserved among several species. Finally,
our data show that molecular screening is useful in the diagnosis of
MODY because it allows one to confirm the diagnosis and to
predict the prognosis as well as the clinical course of the patient.
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Figure 3. Structural features of mutations p.His137Asp,
p.Arg392Ser and p.Gly162Asp GCK. The structure of GCK in the
closed form (PDB code:1v4s) is shown as cyan ribbons. A) p.His137Asp.
Loop 141–144, which is involved in GKRP binding, is in red. His137 is at
the end of the a3 helix. His137 is a capping residue of the helix, which is
terminated by the interaction between side chain of His137 and
Phe133. Asp137 (right) is not able to replace His137 interactions but
adds a new interaction with Lys104. B) p.Gly162Asp. Yellow sticks
represent hydrophobic residues that constitute the core. The location of
Gly162 is marked in red (left of the panel). Asp162 is on the right of the
panel. C) p.Arg392Ser. Residues Asp42, Glu236, Asn240 and Arg392 are
represented by yellow sticks. H-bonds are shown in green. The wild-
type enzyme and the p.Arg392Ser mutant are on the left and right of
the panel, respectively.
doi:10.1371/journal.pone.0001870.g003
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